CONTEXT: Acquired generalized lipodystrophy (AGL) is associated with leptin deficiency as a result of adipose tissue loss and hypertriglyceridemia, insulin resistance, and hepatic steatosis. It may coexist with other autoimmune diseases such as Hashimoto's thyroiditis, rheumatoid arthritis, hemolytic anemia, and chronic active hepatitis. Metreleptin therapy has been shown to improve metabolic abnormalities in lipodystrophy, but the effect on AGL patients with active autoimmune disease is unknown. CASE DESCRIPTION: We report 3 cases of pediatric patients with AGL and distinct active autoimmune diseases who were treated with metreleptin over a period of 4-6 years. Case 1 is a 9-year-old girl with active juvenile dermatomyositis, who was successfully treated with leptin with no worsening of her dermatomoysitis. Case 2 is a 16-year-old female with Graves' disease, who could discontinue all her antidiabetic medication completely with improved triglyceride levels. Case 3 is an 11-year-old boy with active autoimmune hepatitis and chronic urticaria, whose hyperphagia has resolved and his liver enzymes and hepatosplenomegaly have improved. CONCLUSION: Metreleptin therapy is of considerable clinical benefit to reduce insulin resistance and hypertriglyceridemia and did not appear to alter the clinical course of autoimmune disease nor clinical efficacy of immunosuppressive treatments. Our observations suggest that risk or presence of autoimmune disease should not lead to withholding of metreleptin treatment from patients with AGL, but should prompt close clinical follow up in light of cautionary preclinical data.
CONTEXT: Acquired generalized lipodystrophy (AGL) is associated with leptin deficiency as a result of adipose tissue loss and hypertriglyceridemia, insulin resistance, and hepatic steatosis. It may coexist with other autoimmune diseases such as Hashimoto's thyroiditis, rheumatoid arthritis, hemolytic anemia, and chronic active hepatitis. Metreleptin therapy has been shown to improve metabolic abnormalities in lipodystrophy, but the effect on AGLpatients with active autoimmune disease is unknown. CASE DESCRIPTION: We report 3 cases of pediatric patients with AGL and distinct active autoimmune diseases who were treated with metreleptin over a period of 4-6 years. Case 1 is a 9-year-old girl with active juvenile dermatomyositis, who was successfully treated with leptin with no worsening of her dermatomoysitis. Case 2 is a 16-year-old female with Graves' disease, who could discontinue all her antidiabetic medication completely with improved triglyceride levels. Case 3 is an 11-year-old boy with active autoimmune hepatitis and chronic urticaria, whose hyperphagia has resolved and his liver enzymes and hepatosplenomegaly have improved. CONCLUSION: Metreleptin therapy is of considerable clinical benefit to reduce insulin resistance and hypertriglyceridemia and did not appear to alter the clinical course of autoimmune disease nor clinical efficacy of immunosuppressive treatments. Our observations suggest that risk or presence of autoimmune disease should not lead to withholding of metreleptin treatment from patients with AGL, but should prompt close clinical follow up in light of cautionary preclinical data.
Authors: Elif Arioglu Oral; Vinaya Simha; Elaine Ruiz; Alexa Andewelt; Ahalya Premkumar; Peter Snell; Anthony J Wagner; Alex M DePaoli; Marc L Reitman; Simeon I Taylor; Phillip Gorden; Abhimanyu Garg Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: Giuseppe Matarese; Veronica Sanna; Robert I Lechler; Nora Sarvetnick; Silvia Fontana; Serafino Zappacosta; Antonio La Cava Journal: Diabetes Date: 2002-05 Impact factor: 9.461
Authors: Rachel J Perry; Xian-Man Zhang; Dongyan Zhang; Naoki Kumashiro; Joao-Paulo G Camporez; Gary W Cline; Douglas L Rothman; Gerald I Shulman Journal: Nat Med Date: 2014-06-15 Impact factor: 53.440
Authors: April Bingham; Gulnara Mamyrova; Kristina I Rother; Elif Oral; Elaine Cochran; Ahalya Premkumar; David Kleiner; Laura James-Newton; Ira N Targoff; Janardan P Pandey; Danielle Mercatante Carrick; Nancy Sebring; Terrance P O'Hanlon; Maria Ruiz-Hidalgo; Maria Turner; Leslie B Gordon; Jorge Laborda; Steven R Bauer; Perry J Blackshear; Lisa Imundo; Frederick W Miller; Lisa G Rider Journal: Medicine (Baltimore) Date: 2008-03 Impact factor: 1.817
Authors: Iram Hussain; Nivedita Patni; Masako Ueda; Ekaterina Sorkina; Cynthia M Valerio; Elaine Cochran; Rebecca J Brown; Joseph Peeden; Yulia Tikhonovich; Anatoly Tiulpakov; Sarah R S Stender; Elisabeth Klouda; Marwan K Tayeh; Jeffrey W Innis; Anders Meyer; Priti Lal; Amelio F Godoy-Matos; Milena G Teles; Beverley Adams-Huet; Daniel J Rader; Robert A Hegele; Elif A Oral; Abhimanyu Garg Journal: J Clin Endocrinol Metab Date: 2018-03-01 Impact factor: 5.958
Authors: James M Law; David E Morris; Valerie Astle; Ellie Finn; José Joaquín Muros; Lindsay J Robinson; Tabitha Randell; Louise Denvir; Michael E Symonds; Helen Budge Journal: J Endocr Soc Date: 2019-10-11
Authors: Marissa Lightbourne; Anna Wolska; Brent S Abel; Kristina I Rother; Mary Walter; Yevgeniya Kushchayeva; Sungyoung Auh; Robert D Shamburek; Alan T Remaley; Ranganath Muniyappa; Rebecca J Brown Journal: J Endocr Soc Date: 2020-12-04
Authors: Melis Sahinoz; Shafaq Khairi; Ashley Cuttitta; Graham F Brady; Amit Rupani; Rasimcan Meral; Marwan K Tayeh; Peedikayil Thomas; Meredith Riebschleger; Sandra Camelo-Piragua; Jeffrey W Innis; M Bishr Omary; Daniel E Michele; Elif A Oral Journal: Clin Diabetes Endocrinol Date: 2018-03-27